Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9

BMC Cancer

Table 2 Significance tests and AUC values for AGR2, SYCN, REG1B, LOXL2 and CA19.9 analyzed in PDAC versus healthy controls of Sample Set A and B

Comparison group	Marker	Sample set	Median healthy	Median PDAC	Median Ratio	Wilcoxon	AUC^b	Lower 95% CI	Upper 95% CI
Comparison group	Marker	Sample set	Median healthy	Median PDAC	Median Ratio	p-value ^a	AUC^b	Lower 95% CI	Upper 95% CI
PDAC versus healthy controls	SYCN	A	3.82	8.22	2.15	8.38E-07	0.71	0.63	0.78
		B	3.56	12.72	3.57	5.94E-08	0.79^c	0.70	0.87
	AGR2	A	184.85	179.55	0.97	0.38	0.46	0.38	0.54
		B	117.40	173.90	1.48	0.00129	0.67	0.58	0.76
	REG1B	A	4364.00	15232.00	3.49	1.20E-08	0.74	0.67	0.80
		B	4582.00	25380.00	5.54	4.52E-08	0.79^c	0.70	0.86
	LOXL2	A	139.45	172.25	1.24	0.019	0.60	0.52	0.68
		B	106.8	110.70	1.04	0.449	0.54	0.44	0.64
	CA19.9	A	6.00	59.05	9.84	9.54E-16	0.82	0.76	0.88
		B	14.75	144.625	9.81	3.46E-10	0.83^c	0.76	0.90

^a The p-value refers to a comparison between PDAC and Healthy subgroups (Mann–Whitney non-parametric test). Sample sizes are provided in Table 1. Confidence intervals for AUC were calculated by taking 2000 stratified bootstrap samples; ^b AUC, area under the receiver operating characteristic curve; PDAC, pancreatic ductal adenocarcinoma (analogous to use of the term pancreatic cancer elsewhere in this report); ^c No significant difference in AUC was noted between the AUCs of SYCN and REG1B with that of CA19.9 (p > 0.4).

ISSN: 1471-2407